Media Release: 01 March 2011
Australian scientists have developed a reagent with the potential to prevent rejection of transplanted insulin-producing cells into people with Type 1 diabetes – one of the most promising immunology developments in recent years.
The best hope for restoring insulin production is for people to receive transplanted clusters of insulin-producing cells from the pancreas known as ‘Islets of Langerhans'.
Each pancreas has around a million islets, which maintain the body's blood sugar levels in exquisite balance. Islets are obtained from a deceased donor pancreas - and while transplants have been successful for limited periods, islets are fragile, the body rejects donor cells strenuously, and anti-rejection drugs are highly toxic.
And even when heavy duty immunosuppressive drugs are given to a patient, that person still has Type 1 diabetes - the autoimmune disease that destroyed their insulin-producing cells in the first place.
The new reagent, generated in-house by Drs Helen McGuire and Cecile King from Sydney’s Garvan Institute of Medical Research, has the potential to turn this situation around.
Given to diabetic mice for two weeks, starting the day before islet transplantation, the reagent allowed mice to accept the donor cells as their own – with no need for immunosuppressive drugs, and no Type 1 diabetes. Permanently.
The reagent is a cloned a cell surface receptor that mops up a harmful molecule known as IL-21, which appears to cause Type 1 diabetes. The cloned receptors compete with similar receptors on the body’s own killer immune cells, preventing them from destroying the transplant.
The findings are published in the international journal Diabetes, now online.
“Our reagent works as well in our model as drugs that are currently in clinical trials for islet transplantation,” said Dr King.
“Individual tissue types have their own molecular signature, and our bodies usually reject tissues they don’t recognise. In our experiments we used a very strong mismatch, and the mice still accepted the transplants without rejection.”
“If this works in people as it has in mice, then they would only have to take the drug for a brief time-window after surgery– then the transplant would be fine for life.”
“In this study, we’ve shown definitively that if the body’s killer T cells don’t get IL-21, they don’t reject the islet tissue. ”
“The next step would be to trial our IL-21 neutralising agent in people.”
Dr Dorota Pawlak, Head of Research Development at the Juvenile Diabetes Research Foundation, said that the ability to replace insulin producing cells safely in people with Type 1 diabetes without the need for immune suppression would be a revolution for diabetes research. “This finding represents progress and it is important to acknowledge and honour advances that take us closer to finding a cure for Type 1 diabetes.”
This research was supported by the National Health and Medical Research Council and the Juvenile Diabetes Research Foundation.
NOTES TO EDITORS
Type 1 (or juvenile) diabetes affects over 120,000 Australians and incidence is increasing every year. Typically striking young people, it results in the destruction of insulin-producing cells in the pancreas, leaving the sufferer on a daily regime of painful injections and finger-prick tests. Unlike Type 2 diabetes, it is not possible to prevent Type 1. While insulin keeps people alive, it is not a cure and does not prevent the onset of the serious disease complications that dramatically shorten life expectancy.
ABOUT THE JUVENILE DIABETES RESEARCH FOUNDATION
The Juvenile Diabetes Research Foundation is the world's largest not-for-profit supporter of diabetes research, investing more than $100 million in the search to find a cure for Type 1 diabetes each year. Type 1 diabetes is a disease which strikes people suddenly, makes them dependent on multiple daily injections of insulin to survive and at risk of devastating health complications like blindness, kidney failure, heart disease and amputation. The mission of JDRF is constant: to find a cure for diabetes and its complications through the support of research.